San Francisco, Calif. – A Smart Molecule Beats the Mutation Behind Most Pancreatic Cancer. Scientists at UCSF have discovered a new way to disarm a deadly protein that also appears in cancers of the lung, breast and colon. The new molecule permanently modifies a wily cancer-causing mutation, called K-Ras G12D,...
Latest News
Milan, Italy: Researchers have developed a genetic test that can identify how patients with triple negative early-stage breast cancer will respond to immunotherapy drugs. This means that patients who are unlikely to respond to these drugs can avoid the adverse side effects associated with them and can be treated with...
San Francisco, Calif. – In a discovery that could hasten treatment for patients with multiple sclerosis (MS), UC San Francisco scientists have discovered a harbinger in the blood of some people who later went on to develop the disease. In about 1 in 10 cases of MS, the body begins...
San Francisco, Calif. – Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial led by UC San Francisco researchers has found. The approach can extend the time between debilitating drug treatments without...
Santa Barbara, Calif. — UC Santa Barbara researchers and collaborators in Colombia, Brazil and Germany are progressing toward an understanding of mechanisms that underlie Alzheimer’s disease, in particular an early-onset, genetic form that has afflicted generations of an extended family in Colombia. They also shed some light on a woman...
ATLANTA, GA — UCB, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). In addition, a second sBLA...
ATLANTA — UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it will be presenting results from across its portfolio in generalized myasthenia gravis (gMG) at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting and the Myasthenia Gravis Association of America Scientific Session taking place...
ATLANTA — UCB, a global biopharmaceutical company, today announced that it will present six abstracts in hidradenitis suppurativa (HS) at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) in Phoenix, Arizona. Data and analyses in HS will be presented across two oral presentations and four posters. “The data to...
Chicago, Illinois – The University of Chicago Medicine Comer Children’s Hospital will be among the first in the country to offer gene therapy for sickle cell disease in patients 12 years and older, after federal regulators approved two new treatments in December 2023. Thousands of patients with sickle cell disease...
Los Angeles, Calif. – Samara Rahman, 74, considers herself lucky. She gets to take walks on the beach, go swimming and ride her bike — all things that were taken from her when she was diagnosed with pancreatic cancer in November of 2022. Pancreatic cancer is the third leading cause of cancer-related deaths...